Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

Abstract excerpt

Anti-CD38 monoclonal antibodies (mAbs) are approved for multiple myeloma (MM) in the first-line and relapsed/refractory settings. 1,2Resistance portends a poor prognosis, yet underlying mechanisms have not been well characterized. 3Despite the generally high CD38 expression on most malignant plasma cells (PCs), variation in the surface level may affect the clinical efficacy of targeted therapy....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Calcium signaling and nucleotide metabolism
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Synthesis and Biological Evaluation